Business Context and Reporting Period
This Form 8-K is a current report filed by RXi Pharmaceuticals Corporation (referred to in metadata as Phio Pharmaceuticals Corp.) on May 31, 2012. The filing serves to disclose a press release issued on the same date under Item 7.01 (Regulation FD Disclosure). The registrant is incorporated in Delaware with principal executive offices in Worcester, Massachusetts.
Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This document is a procedural filing to incorporate a press release by reference and does not contain a financial statement or detailed financial data within the provided text.
Material Changes
No material financial changes versus a prior comparable period are detailed in the text of this filing. The report indicates the furnishing of a press release (Exhibit 99.1) but does not summarize the content of that release within the body of the 8-K.
Guidance, Outlook, and Risks
The filing explicitly states that the information in Item 7.01 and the attached press release is "furnished" and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934. Consequently, this information is not incorporated by reference into other filings. No specific guidance, outlook, risks, or contingencies are described in the provided text.
Key Facts for Investor Verification
- Verify the content of the press release attached as Exhibit 99.1, as the 8-K itself contains no substantive operational or financial details.
- Note that the press release information is not legally "filed" under the Exchange Act and may not be incorporated by reference into future filings.
- Confirm the company's current name and status, as the metadata lists "Phio Pharmaceuticals Corp." while the filing header lists "RXi Pharmaceuticals Corporation."